Phase III study of TriLipix in combo with Crestor meets primary endpoints
Tuesday, June 03, 2008 18:00 IST Seattle
New phase III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix (ABT-335) combined with AstraZeneca's rosuvastatin (Crestor) led to greater improvements